Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 Dec 10:14:867.
doi: 10.1186/1471-2164-14-867.

Association of homocysteine with type 2 diabetes: a meta-analysis implementing Mendelian randomization approach

Affiliations
Meta-Analysis

Association of homocysteine with type 2 diabetes: a meta-analysis implementing Mendelian randomization approach

Tao Huang et al. BMC Genomics. .

Abstract

Background: We tested the hypothesis that elevated homocysteine (Hcy) level is causally associated with increased risk of type 2 diabetes mellitus (T2DM).

Results: The meta-analysis and Mendelian randomization analysis were performed among 4011 cases and 4303 controls. The absolute pooled mean Hcy concentration in subjects with MTHFR 677TT was 5.55 μmol/L (95% CI, 1.33 to 9.77) greater than that in subjects with MTHFR 677CC in T2DM. Overall, the T allele of the MTHFR 677 C > T conferred a greater risk for T2DM [Random effect (RE) OR = 1.31(1.17-1.64), I² = 41.0%, p = 0.055]. The random effect (RE) pooled OR associated with T2DM for MTHFR 677TT relative to the 677CC was [RE OR = 1.38(1.18-1.62)]. The fixed-effect pooled OR of the association for the MTHFR 677 TT vs CT was 1.29 (95% CI, 1.09-1.51). MTHFR 677 TT showed a significantly higher risk for T2DM compared with MTHFR 677 CC + CT [Fixed effect (FE) OR = 1.32(1.14-1.54), I² = 0.0%, p = 0.686]. The absolute pooled mean Hcy concentration in individuals with T2DM was 0.94 μmol/L (95% CI, 0.40-1.48) greater than that in control subjects. The estimated causal OR associated with T2DM was 1.29 for 5 μmol/L increment in Hcy.

Conclusions: Our findings provided strong evidence on the causal association of Hcy level with the development of T2DM.

PubMed Disclaimer

Figures

Figure 1
Figure 1
PRISMA flow diagram for selection of studies in the meta-analysis.
Figure 2
Figure 2
Summary estimates for the effect size (ES) in plasma Hcy between the MTHFR genotypes (TT vs CC) in type 2 diabetes patients. aT2DM patients with nephropathy, bT2DM patients without nephropathy.
Figure 3
Figure 3
Summary estimates for the effect size (ES) in plasma Hcy between the MTHFR genotypes (TT vs CT) in type 2 diabetes patients. aT2DM patients with nephropathy, bT2DM patients without nephropathy.
Figure 4
Figure 4
Summary estimates for the OR of MTHFR 677 C > T in genotype contrasts (TT vs CC), the OR with the 95% confidence interval is shown. Studies are displayed by descending order of publication year.
Figure 5
Figure 5
Summary estimates for the OR of MTHFR 677 C > T in allele contrasts (T vs C), the OR with the 95% confidence interval is shown. Studies are displayed by descending order of publication year.
Figure 6
Figure 6
Forest plot of standardized mean difference (SMD) in Hcy between subjects with and without type 2 diabetes in included studies. aT2DM patients with nephropathy, bT2DM patients without nephropathy.
Figure 7
Figure 7
The potential causal relation between Hcy and T2DM risk was explored by using Mendelian randomization. Calculation of an unconfounded estimate of the effect of an increase in Hcy of 1 μmol/L on the risk of T2DM based on the concept of Mendelian randomization.

Similar articles

Cited by

References

    1. King GL, Kunisaki M, Nishio Y, Inoguchi T, Shiba T. et al.Biochemical and molecular mechanisms in the development of diabetic vascular complications. Diabetes. 1996;14:S105–S108. - PubMed
    1. Hoogeveen EK, Kostense PJ, Beks PJ, MacKaay AJC, Jakobs C. et al.Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus - a population-based. Arterioscler Thromb Vasc Biol. 1998;14:133–138. doi: 10.1161/01.ATV.18.1.133. - DOI - PubMed
    1. Meigs JB, Jacques PF, Selhub J, Singer DE, Nathan DM. et al.Fasting plasma homocysteine levels in the insulin resistance syndrome - the Framingham offspring study. Diabetes Care. 2001;14:1403–1410. doi: 10.2337/diacare.24.8.1403. - DOI - PubMed
    1. Buysschaert M, Dramais AS, Wallemacq PE, Hermans MP. Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes Care. 2000;14:1816–1822. doi: 10.2337/diacare.23.12.1816. - DOI - PubMed
    1. Kark JD, Selhub J, Bostom A, Adler B, Rosenberg IH. Plasma homocysteine and all-cause mortality in diabetes. Lancet. 1999;14:1936–1937. - PubMed

Publication types

Substances